WO1999001167A1 - Process for modifiying surfaces using the reaction product of a water-insoluble polymer and a polyalklene imine - Google Patents

Process for modifiying surfaces using the reaction product of a water-insoluble polymer and a polyalklene imine Download PDF

Info

Publication number
WO1999001167A1
WO1999001167A1 PCT/US1997/020055 US9720055W WO9901167A1 WO 1999001167 A1 WO1999001167 A1 WO 1999001167A1 US 9720055 W US9720055 W US 9720055W WO 9901167 A1 WO9901167 A1 WO 9901167A1
Authority
WO
WIPO (PCT)
Prior art keywords
biologically active
active agent
imine
reaction product
article
Prior art date
Application number
PCT/US1997/020055
Other languages
French (fr)
Inventor
David F. Wirt
Larry M. Sirvio
Original Assignee
Minnesota Mining And Manufacturing Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining And Manufacturing Company filed Critical Minnesota Mining And Manufacturing Company
Priority to EP97946507A priority Critical patent/EP1021216A1/en
Priority to AU51662/98A priority patent/AU5166298A/en
Priority to JP50860499A priority patent/JP4339413B2/en
Publication of WO1999001167A1 publication Critical patent/WO1999001167A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0029—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using an intermediate layer of polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/31504—Composite [nonstructural laminate]
    • Y10T428/31855—Of addition polymer from unsaturated monomers
    • Y10T428/31909—Next to second addition polymer from unsaturated monomers

Definitions

  • the invention relates to modifying the surface of an article.
  • Surfaces of, e.g., medical devices must often be modified.
  • the surfaces of medical devices that are in direct contact with blood or blood products e.g., blood oxygenators, blood pumps, catheters, and tubing
  • biologically active agents such as heparin or derivatives thereof to make such surfaces nonthrombogenic in an effort to prevent clotting or clot formation related to surface contact with blood or blood products.
  • the invention features a process for modifying the surface of an article that includes treating the surface with a solution that includes (a) an organic solvent, and (b) the reaction product of a substantially water insoluble polymer and a polyalkylene imine (e.g., polyethylene imine) to form a modified surface.
  • a solution that includes (a) an organic solvent, and (b) the reaction product of a substantially water insoluble polymer and a polyalkylene imine (e.g., polyethylene imine) to form a modified surface.
  • the treated surface may be reacted further with a biologically active agent.
  • the biologically active agent may include negatively charged materials.
  • biologically active agents include anti-thrombotic agents (e.g., a glycosaminoglycan (or a derivative thereof) such as heparin or a heparin derivative).
  • suitable biologically active agents include heparin sulfate, hyaluronic acid, dermatan sulfate, chitosan, derivatives thereof, and combinations thereof.
  • Preferred substantially water-insoluble polymers include functional groups such as ester groups that are capable of forming a covalent bond with the polyalkylene imine.
  • Specific examples include the reaction product of an alkyl acrylate and an alkyl methacrylate (e.g., isooctyl acrylate and methyl methacrylate); the reaction product of an alkyl methacrylate, an alkylacrylate, and N-vinyl pyrrolidone (e.g., methyl methacrylate, isooctyl acrylate, and N-vinyl pyrrolidone); and the reaction product of an alkyl acrylate, an alkyl methacrylate, and a hydroxyalkyl methacrylate (e.g., isooctyl acrylate, methyl methacrylate, and hydroxypropyl methacrylate).
  • the acrylate, methacrylate, and N-vinyl pyrrolidone may be provided in the form
  • the invention also features an article that includes a substrate having a modified surface that includes the reaction product of a substantially water insoluble polymer and a polyalkylene imine.
  • the article may further include a biologically active agent bound to the surface.
  • a “biologically active agent” is a material which, when in contact with a patient's blood, plasma, or other body fluids or tissues under physiological conditions, exhibits biological activity.
  • a material such as heparin is “biologically active” in the sense that it acts as an anti-coagulant in the presence of blood.
  • the invention provides a simple and effective means for modifying the surface of an article, e.g., such that when in contact with a patient's blood, plasma, or other body fluids, the surface does not cause an adverse physiological reaction.
  • the present invention provides a process for producing modified surfaces (e.g., the surfaces of medical devices such as filters, membranes, tubes, catheters, oxygenator, intravascular probes, blood pumps, blood gas sensing devices, and the like).
  • the surface may be a polymer, ceramic, or metal surface.
  • suitable polymer surfaces include polypropylene, poly (vinyl chloride), poly (methyl methacrylate), polytetrafluoroethylene, polysulfone, silicone rubber, poly (ethylene terephthalate), polycarbonate, polyethylene, polystyrene, and polyurethane.
  • the surface is contacted with a priming solution that contains an organic solvent and the reaction product of a polyalkylene imine, such as polyethylene imine, and a substantially water insoluble polymer, and then dried.
  • a priming solution that contains an organic solvent and the reaction product of a polyalkylene imine, such as polyethylene imine, and a substantially water insoluble polymer, and then dried.
  • the resulting primed surface is capable of binding with a biologically active agent.
  • the system is designed to be functional after a single coating step, the solution may be coated on the surface and dried as many times as is necessary to achieve the desired concentration of functional groups on the surface. The particular amount of coating and concentration of functional groups on the surface will depend upon the particular application for which the treated surface is intended.
  • the surface may then be contacted with a biologically active agent to bind the biologically active agent to the primed surface.
  • the biologically active agent may be an anti-thrombotic agent (e.g., a glycosaminoglycan (or derivative thereof) such as heparin or a heparin derivative), an anti-microbial agent, a therapeutic agent (e.g., a drug or growth factor), an enzyme, or a cell attachment protein.
  • suitable biologically active agents include heparin, heparan sulfate, hyaluronic acid, dermatan sulfate, chitosan, and derivatives thereof. The agents may be used alone or in combination with each other.
  • Binding may be either ionic or covalent, with covalent being preferred.
  • the biologically active agent include one or more negatively charged groups.
  • the biologically active agent may then be treated with a crosslinking agent, if desired.
  • covalent binding it is preferred to contact the primed surface with a biologically active agent having free aldehyde groups (generated, e.g., by periodate oxidation) in the presence of a reducing agent such as sodium cyanoborohydride.
  • a biologically active agent having free aldehyde groups generated, e.g., by periodate oxidation
  • a reducing agent such as sodium cyanoborohydride.
  • the covalent binding most likely occurs via formation of a Schiff s base initially, which is then readily reduced to a secondary amine in the presence of the sodium cyanoborohydride.
  • Covalent binding may also be accomplished using a coupling agent such as a carbodiimide, rather than sodium cyanoborohydride.
  • a coupling agent such as a carbodiimide, rather than sodium cyanoborohydride.
  • the covalent linkage occurs between carboxylate groups on the biologically active agent and amine groups on the primed surface.
  • Preferred priming solutions include between about 0.1 to about 20% solids in a solution that includes between about 50 and about 99.9% organic solvent and up to about 50% water.
  • the weight to weight ratio of substantially water insoluble polymer to polyethylene imine is preferably between about 0.1 : 1 and about 10:1, more preferably about 4 : 1.
  • Suitable polyalkylene imines are those having an average molecular weight of between about 300 and 1,000,000.
  • a suitable polyalkylene imine is polyethylene imine having an average molecular weight of 750,000, available from the Aldrich Chemical Co., Milwaukee, Wisconsin.
  • Preferred substantially water insoluble polymers are those polymers that provide functional groups capable of forming a covalent bond with the amine groups of the polyalkylene imine while not interfering with the ability of the polyalkylene imine to bind to a biologically active agent.
  • the polymer preferably is soluble in those organic solvents in which the polyalkylene imine is soluble.
  • Suitable substantially water insoluble polymers include substantially water insoluble acrylate polymers such as, e.g., alkyl acrylate-alkyl methacrylate copolymers (e.g., copolymers of isooctyl acrylate and methyl methacrylate), alkyl methacrylate-alkyl acrylate-N-vinyl pyrrolidone terpolymers (e.g., methyl methacrylate-isooctyl acrylate-N-vinyl pyrrolidone), and alkyl acrylate-alkyl methacrylate-hydroxyalkyl methacrylate terpolymers (e.g., isooctyl acrylate-methyl methacrylate-hydroxypropyl methacrylate).
  • alkyl acrylate-alkyl methacrylate copolymers e.g., copolymers of isooctyl acrylate and methyl methacrylate
  • Preferred organic solvents are those capable of dissolving both the substantially water insoluble polymer and polyalkylene imine, and rapidly evaporating after the application of the priming solution to the substrate surface.
  • Suitable organic solvents include tetrahydrofuran and alkyl alcohols such as, e.g., methanol, ethanol, and isopropyl alcohol.
  • Methyl methacrylate monomers, isooctyl acrylate monomers and N-vinyl pyrrolidone monomers were polymerized as described in Examples 2-8, formulation D of U.S. Patent No. 4,584, 192, to form a terpolymer.
  • the terpolymer was then repeatedly washed and distilled so as to remove the acetone. Once the acetone was removed, the terpolymer was placed in isopropyl alcohol.
  • the terpolymer solution and polyethylene imine were then placed in a solution of isopropyl alcohol and water.
  • the resulting solution contained 4: 1 polyethylene imine/terpolymer, 2.5% solids solution in 82.5% isopropyl alcohol and 15% water.
  • the solution was allowed to react for four hours at 50EC, after which it was coated on a piece of woven polyester. After evaporation of the solvent, a portion of the sample was separated and rinsed with water. It was then stained with 8-hydroxy-7-(4-sulfo-l-naphthylazo)-5-quinoline sulfonic acid (SNAZOXS), which revealed the presence of PEI.
  • SNAZOXS 8-hydroxy-7-(4-sulfo-l-naphthylazo)-5-quinoline sulfonic acid
  • the remaining portion of the sample was rinsed with 25% saline solution and then stained with SNAZOXS. Staining also revealed the presence of PEI, demonstrating that the PEI does not rinse off even with saline solution.
  • IOA/MMA/hydroxypropyl methacrylate (HPMA) terpolymer having 50 parts IOA, 40 parts MMA and 10 parts HPMA, was dissolved in 35g of THF.
  • PEI was added to the IOA/MMA/HPMA THF solution and the mixture was allowed to react for four hours at 50EC.
  • the solution was coated on a piece of woven polyester. After evaporation of the solvent, the polyester sample was rinsed with a 25% saline solution. The polyester sample was then stained with SNAZOXS, which revealed the presence of PEI.
  • the heparinized sample was then rinsed for five minutes in 25% saline solution to remove ionically bound heparin, leaving only covalently bound heparin.
  • the sample was subjected to a thrombin inhibition assay following the procedure described in Sirvio et al., U.S. Patent No. 5,532,311 (hereby incorporated by reference). The results of the assay demonstrated that the activity of heparin on the sample surface corresponded to 0.14 micrograms/cm 2 .

Abstract

A process for modifying a surface of an article that includes treating a surface with a solution that includes an organic solvent, and the reaction product of a substantially water insoluble polymer and a polyalkylene imine to form a modified surface. Additionally, a biologically active agent such as an anti-thrombotic agent may be attached to the modified surface.

Description

PROCESS FOR MODIFYING SURFACES USING THE
REACTION PRODUCT OF A WATER-INSOLUBLE
POLYMER AND A POLYALKYLENE IMINE
The invention relates to modifying the surface of an article. Surfaces of, e.g., medical devices must often be modified. For example, the surfaces of medical devices that are in direct contact with blood or blood products (e.g., blood oxygenators, blood pumps, catheters, and tubing) have been treated with biologically active agents such as heparin or derivatives thereof to make such surfaces nonthrombogenic in an effort to prevent clotting or clot formation related to surface contact with blood or blood products.
In one aspect, the invention features a process for modifying the surface of an article that includes treating the surface with a solution that includes (a) an organic solvent, and (b) the reaction product of a substantially water insoluble polymer and a polyalkylene imine (e.g., polyethylene imine) to form a modified surface.
In one preferred embodiment, the treated surface may be reacted further with a biologically active agent. The biologically active agent may include negatively charged materials. Specific examples of biologically active agents include anti-thrombotic agents (e.g., a glycosaminoglycan (or a derivative thereof) such as heparin or a heparin derivative). Other examples of suitable biologically active agents include heparin sulfate, hyaluronic acid, dermatan sulfate, chitosan, derivatives thereof, and combinations thereof.
Preferred substantially water-insoluble polymers include functional groups such as ester groups that are capable of forming a covalent bond with the polyalkylene imine. Specific examples include the reaction product of an alkyl acrylate and an alkyl methacrylate (e.g., isooctyl acrylate and methyl methacrylate); the reaction product of an alkyl methacrylate, an alkylacrylate, and N-vinyl pyrrolidone (e.g., methyl methacrylate, isooctyl acrylate, and N-vinyl pyrrolidone); and the reaction product of an alkyl acrylate, an alkyl methacrylate, and a hydroxyalkyl methacrylate (e.g., isooctyl acrylate, methyl methacrylate, and hydroxypropyl methacrylate). The acrylate, methacrylate, and N-vinyl pyrrolidone may be provided in the form of monomers, oligomers, or a combination thereof.
The invention also features an article that includes a substrate having a modified surface that includes the reaction product of a substantially water insoluble polymer and a polyalkylene imine. The article may further include a biologically active agent bound to the surface.
Throughout this application the following definitions apply:
A "biologically active agent" is a material which, when in contact with a patient's blood, plasma, or other body fluids or tissues under physiological conditions, exhibits biological activity. For instance, a material such as heparin is "biologically active" in the sense that it acts as an anti-coagulant in the presence of blood.
The invention provides a simple and effective means for modifying the surface of an article, e.g., such that when in contact with a patient's blood, plasma, or other body fluids, the surface does not cause an adverse physiological reaction.
The present invention provides a process for producing modified surfaces (e.g., the surfaces of medical devices such as filters, membranes, tubes, catheters, oxygenator, intravascular probes, blood pumps, blood gas sensing devices, and the like). The surface may be a polymer, ceramic, or metal surface. Examples of suitable polymer surfaces include polypropylene, poly (vinyl chloride), poly (methyl methacrylate), polytetrafluoroethylene, polysulfone, silicone rubber, poly (ethylene terephthalate), polycarbonate, polyethylene, polystyrene, and polyurethane.
In general, the surface is contacted with a priming solution that contains an organic solvent and the reaction product of a polyalkylene imine, such as polyethylene imine, and a substantially water insoluble polymer, and then dried. The resulting primed surface is capable of binding with a biologically active agent. Although the system is designed to be functional after a single coating step, the solution may be coated on the surface and dried as many times as is necessary to achieve the desired concentration of functional groups on the surface. The particular amount of coating and concentration of functional groups on the surface will depend upon the particular application for which the treated surface is intended.
The surface may then be contacted with a biologically active agent to bind the biologically active agent to the primed surface. The biologically active agent may be an anti-thrombotic agent (e.g., a glycosaminoglycan (or derivative thereof) such as heparin or a heparin derivative), an anti-microbial agent, a therapeutic agent (e.g., a drug or growth factor), an enzyme, or a cell attachment protein. Other examples of suitable biologically active agents include heparin, heparan sulfate, hyaluronic acid, dermatan sulfate, chitosan, and derivatives thereof. The agents may be used alone or in combination with each other.
Binding may be either ionic or covalent, with covalent being preferred. In the case of ionic binding, it is preferred that the biologically active agent include one or more negatively charged groups. Following addition of the biologically active agent, the biologically active agent may then be treated with a crosslinking agent, if desired.
In the case of covalent binding, it is preferred to contact the primed surface with a biologically active agent having free aldehyde groups (generated, e.g., by periodate oxidation) in the presence of a reducing agent such as sodium cyanoborohydride. The covalent binding most likely occurs via formation of a Schiff s base initially, which is then readily reduced to a secondary amine in the presence of the sodium cyanoborohydride.
Covalent binding may also be accomplished using a coupling agent such as a carbodiimide, rather than sodium cyanoborohydride. In this case, the covalent linkage occurs between carboxylate groups on the biologically active agent and amine groups on the primed surface.
Preferred priming solutions include between about 0.1 to about 20% solids in a solution that includes between about 50 and about 99.9% organic solvent and up to about 50% water. The weight to weight ratio of substantially water insoluble polymer to polyethylene imine is preferably between about 0.1 : 1 and about 10:1, more preferably about 4 : 1.
Suitable polyalkylene imines are those having an average molecular weight of between about 300 and 1,000,000. One example of a suitable polyalkylene imine is polyethylene imine having an average molecular weight of 750,000, available from the Aldrich Chemical Co., Milwaukee, Wisconsin. Preferred substantially water insoluble polymers are those polymers that provide functional groups capable of forming a covalent bond with the amine groups of the polyalkylene imine while not interfering with the ability of the polyalkylene imine to bind to a biologically active agent. The polymer preferably is soluble in those organic solvents in which the polyalkylene imine is soluble. Suitable substantially water insoluble polymers include substantially water insoluble acrylate polymers such as, e.g., alkyl acrylate-alkyl methacrylate copolymers (e.g., copolymers of isooctyl acrylate and methyl methacrylate), alkyl methacrylate-alkyl acrylate-N-vinyl pyrrolidone terpolymers (e.g., methyl methacrylate-isooctyl acrylate-N-vinyl pyrrolidone), and alkyl acrylate-alkyl methacrylate-hydroxyalkyl methacrylate terpolymers (e.g., isooctyl acrylate-methyl methacrylate-hydroxypropyl methacrylate).
Examples of alkyl methacrylate-alkyl acrylate-N-vinyl pyrrolidone terpolymers, and their methods of manufacture, are described in U.S. Patent No. 4,584,192 (Dell), incorporated herein by reference.
Preferred organic solvents are those capable of dissolving both the substantially water insoluble polymer and polyalkylene imine, and rapidly evaporating after the application of the priming solution to the substrate surface. Suitable organic solvents include tetrahydrofuran and alkyl alcohols such as, e.g., methanol, ethanol, and isopropyl alcohol.
The invention will now be further described by way of the following non- limiting examples.
Example 1
Methyl methacrylate monomers, isooctyl acrylate monomers and N-vinyl pyrrolidone monomers were polymerized as described in Examples 2-8, formulation D of U.S. Patent No. 4,584, 192, to form a terpolymer. The terpolymer was then repeatedly washed and distilled so as to remove the acetone. Once the acetone was removed, the terpolymer was placed in isopropyl alcohol.
The terpolymer solution and polyethylene imine were then placed in a solution of isopropyl alcohol and water. The resulting solution contained 4: 1 polyethylene imine/terpolymer, 2.5% solids solution in 82.5% isopropyl alcohol and 15% water. The solution was allowed to react for four hours at 50EC, after which it was coated on a piece of woven polyester. After evaporation of the solvent, a portion of the sample was separated and rinsed with water. It was then stained with 8-hydroxy-7-(4-sulfo-l-naphthylazo)-5-quinoline sulfonic acid (SNAZOXS), which revealed the presence of PEI.
The remaining portion of the sample was rinsed with 25% saline solution and then stained with SNAZOXS. Staining also revealed the presence of PEI, demonstrating that the PEI does not rinse off even with saline solution.
Example 2
Two grams (g) of a isooctyl acrylate/methyl methacrylate (IOA/MMA) copolymer, having 55 parts IOA and 45 parts MMA, was dissolved in 35g of tetrahydrofiiran (THF). Two grams of polyethylene imine (PEI) (average molecular weight of 750,000, available from Aldrich Chemical Co., Milwaukee, Wisconsin) was added to the IOA/MMA THF solution and the mixture was allowed to react for four hours at 50EC. The solution was coated on a piece of woven polyester. After evaporation of the solvent, the polyester sample was rinsed with a 25% saline solution. The polyester sample was then stained with 8-hydroxy-7-(4-sulfo-l- naphthylazo)-5-quinoline sulfonic acid (SNAZOXS), which revealed the presence ofPEI.
Example 3
Two grams of IOA/MMA/hydroxypropyl methacrylate (HPMA) terpolymer, having 50 parts IOA, 40 parts MMA and 10 parts HPMA, was dissolved in 35g of THF. Two grams of PEI was added to the IOA/MMA/HPMA THF solution and the mixture was allowed to react for four hours at 50EC. The solution was coated on a piece of woven polyester. After evaporation of the solvent, the polyester sample was rinsed with a 25% saline solution. The polyester sample was then stained with SNAZOXS, which revealed the presence of PEI.
Example 4 An isooctyl acrylate-methyl methacrylate-N-vinyl pyrollidone terpolymer was prepared following the procedure of Example 1 except that a polycarbonate sample was dip coated in the solution and allowed to dry. Next, the dried sample was rinsed thoroughly with water, after which heparin was attached to the primed polycarbonate surface by immersing the sample in a citrate-buffered saline solution containing 0.04% periodate oxidized heparin and 0.004% sodium cyanoborohydride (pH = 3.9) for a period of 30 minutes at 50EC. The heparinized sample was then rinsed for five minutes in 25% saline solution to remove ionically bound heparin, leaving only covalently bound heparin. The sample was subjected to a thrombin inhibition assay following the procedure described in Sirvio et al., U.S. Patent No. 5,532,311 (hereby incorporated by reference). The results of the assay demonstrated that the activity of heparin on the sample surface corresponded to 0.14 micrograms/cm2.

Claims

What is claimed is:
1. A process for modifying a surface of an article comprising: treating a surface with a solution comprising
(a) an organic solvent, and (b) the reaction product of a substantially water insoluble polymer and a polyalkylene imine to form a modified surface.
2. The process of claim 1, further comprising contacting said modified surface with a biologically active agent to bind said biologically active agent to said surface.
3. The process of claim 2, wherein said biologically active agent comprises a negatively charged material.
4. The process of claim 2, wherein said biologically active agent comprises an anti-thrombotic agent.
5. The process of claim 2, wherein said biologically active agent comprises a glycosaminoglycan or a derivative thereof.
6. The process of claim 2, wherein said biologically active agent comprises heparin or a derivative thereof.
7. An article comprising a substrate having a surface that has been modified using the process of claim 1.
8. The article of claim 7, wherein said polyalkylene imine comprises polyethylene imine.
9. The article of claim 7, further comprising a biologically active agent bound to said surface.
10. The article of claim 9, wherein said biologically active agent comprises a negatively charged material.
PCT/US1997/020055 1997-07-01 1997-10-31 Process for modifiying surfaces using the reaction product of a water-insoluble polymer and a polyalklene imine WO1999001167A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97946507A EP1021216A1 (en) 1997-07-01 1997-10-31 Process for modifiying surfaces using the reaction product of a water-insoluble polymer and a polyalklene imine
AU51662/98A AU5166298A (en) 1997-07-01 1997-10-31 Process for modifiying surfaces using the reaction product of a water-insoluble polymer and a polyalklene imine
JP50860499A JP4339413B2 (en) 1997-07-01 1997-10-31 Surface modification method using reaction mixture of water-insoluble polymer and polyalkylenimine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/886,720 US6146771A (en) 1997-07-01 1997-07-01 Process for modifying surfaces using the reaction product of a water-insoluble polymer and a polyalkylene imine
US08/886,720 1997-07-01

Publications (1)

Publication Number Publication Date
WO1999001167A1 true WO1999001167A1 (en) 1999-01-14

Family

ID=25389614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/020055 WO1999001167A1 (en) 1997-07-01 1997-10-31 Process for modifiying surfaces using the reaction product of a water-insoluble polymer and a polyalklene imine

Country Status (5)

Country Link
US (1) US6146771A (en)
EP (1) EP1021216A1 (en)
JP (1) JP4339413B2 (en)
AU (1) AU5166298A (en)
WO (1) WO1999001167A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027444A1 (en) * 1998-11-09 2000-05-18 Ecole Polytechnique Federale De Lausanne Functionalised polymers for tissue engineering
WO2000041739A1 (en) * 1999-01-15 2000-07-20 University Of Utah Research Foundation Attachment of acid moiety-containing biomolecules to activated polymeric surfaces
EP1088564A1 (en) * 1999-09-30 2001-04-04 Orbus Medical Technologies, Inc. Intraluminal device, coating for such device, as well as a method for preparing the intraluminal device

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6478808B2 (en) 1997-12-17 2002-11-12 Closys Corporation Clotting cascade initiating apparatus and methods of use and methods of closing wounds
US6159232A (en) 1997-12-16 2000-12-12 Closys Corporation Clotting cascade initiating apparatus and methods of use and methods of closing wounds
US6482223B1 (en) 1997-12-16 2002-11-19 Closys Corporation Clotting cascade initiating apparatus and methods of use
US20030069601A1 (en) * 1998-12-15 2003-04-10 Closys Corporation Clotting cascade initiating apparatus and methods of use
CN1338970A (en) * 1999-12-08 2002-03-06 巴克斯特国际公司 Microporous filter membrane, manufacture thereof and separator therewith
US6982058B2 (en) * 1999-12-08 2006-01-03 Baxter International, Inc. Method for fabricating three dimensional structures
US20030168396A1 (en) * 1999-12-08 2003-09-11 Jacobson James D. Monolithic filter body and fabrication technique
JP2007516054A (en) * 2003-12-23 2007-06-21 アドバンスト メディカル オプティクス， インコーポレーテッド Lubricating biocompatible coating for medical devices
US8053078B2 (en) 2005-04-11 2011-11-08 Abbott Medical Optics Inc. Medical devices having soft, flexible lubricious coatings
US10231721B2 (en) 2010-06-24 2019-03-19 St. Croix Surgical Systems, Llc Failsafe percutaneous wound barrier
WO2015009431A1 (en) * 2013-07-19 2015-01-22 Rarecyte, Inc. Solution and method for adhering suspension components to a substrate
EP3078389B1 (en) * 2013-11-28 2020-04-01 Toray Industries, Inc. Antithrombotic material
WO2016089966A1 (en) * 2014-12-02 2016-06-09 Rarecyte, Inc. Solution and method for adhering suspension components to a substrate
EP3634528B1 (en) 2017-06-07 2023-06-07 Shifamed Holdings, LLC Intravascular fluid movement devices, systems, and methods of use
EP3710076B1 (en) 2017-11-13 2023-12-27 Shifamed Holdings, LLC Intravascular fluid movement devices, systems, and methods of use
EP3746149A4 (en) 2018-02-01 2021-10-27 Shifamed Holdings, LLC Intravascular blood pumps and methods of use and manufacture
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
WO2021062265A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0351314A2 (en) * 1988-07-11 1990-01-17 Terumo Kabushiki Kaisha Medical material and medical implement
EP0693293A1 (en) * 1994-07-07 1996-01-24 Terumo Kabushiki Kaisha Medical instruments that exhibit surface lubricity when wetted
WO1997046590A1 (en) * 1996-06-03 1997-12-11 Gore Enterprise Holdings, Inc. Materials and methods for the immobilization of bioactive species onto polymeric substrates

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2016962A (en) * 1932-09-27 1935-10-08 Du Pont Process for producing glucamines and related products
US2918462A (en) * 1956-01-20 1959-12-22 Ciba Pharm Prod Inc Process for the preparation of amino-aldehydes
US2954358A (en) * 1957-10-01 1960-09-27 Rohm & Haas Aqueous dispersion containing acrylic acid copolymer and aliphatic polyepoxide
US3096602A (en) * 1962-01-05 1963-07-09 Dow Chemical Co Packaging method
US3325346A (en) * 1964-06-26 1967-06-13 Chemirad Corp Process of making paper using reaction product of polyethyleneimine and polyisocyanate
SE306597B (en) * 1964-12-17 1968-12-02 Incentive Ab
US3453194A (en) * 1966-08-03 1969-07-01 Dow Corning Anticoagulant surfaces produced by radiation grafting heparin to a silicone substrate
US3617344A (en) * 1966-08-05 1971-11-02 Us Health Education & Welfare Nonthrombogenic plastic surfaces and preparation thereof
US3475358A (en) * 1967-10-31 1969-10-28 Amicon Corp Anti-thrombogenic material
US3639141A (en) * 1968-09-16 1972-02-01 Cordis Corp Heparinization of plastic
DE1952725C3 (en) * 1969-10-20 1973-11-29 Huels Chemische Werke Ag Process for the production of saturated monocyclic monoterpenes from ethers of monocyclic monoterpenes
US3616935A (en) * 1970-02-05 1971-11-02 Dow Chemical Co Preparation of antithrombogenic surfaces
US3796634A (en) * 1970-03-19 1974-03-12 Us Health Education & Welfare Insolubilized biologically active enzymes
FR2087506A5 (en) * 1970-05-21 1971-12-31 Rhone Poulenc Sa
US3846353A (en) * 1970-06-08 1974-11-05 Department Of Health Education Nonthrombogenic plastic material and method for making the same
US3853804A (en) * 1970-08-14 1974-12-10 California Inst Of Techn Ionic block elastomeric polymers
US3755218A (en) * 1970-08-14 1973-08-28 California Inst Of Techn Ionically bonded block elastomeric copolymers of a polyquaternary polyurethane and heparin
US3673612A (en) * 1970-08-28 1972-07-04 Massachusetts Inst Technology Non-thrombogenic materials and methods for their preparation
DE2148011C3 (en) * 1970-10-05 1978-11-09 Aminkemi Ab Process for producing non-thrombogenic plastic surfaces
US4265827A (en) * 1971-03-08 1981-05-05 Monsanto Company Catalytic asymmetric hydrogenation
US3786113A (en) * 1972-02-14 1974-01-15 Nat Patent Dev Corp Composition containing an acrylic resin,a polyethyleneimine,and a polyepoxide
US3826678A (en) * 1972-06-06 1974-07-30 Atomic Energy Commission Method for preparation of biocompatible and biofunctional materials and product thereof
US3947352A (en) * 1974-05-31 1976-03-30 Pedro Cuatrecasas Polysaccharide matrices for use as adsorbents in affinity chromatography techniques
GB1495746A (en) * 1974-07-05 1977-12-21 Ciba Geigy Ag Polymerisation of unsaturated amides
US4001583A (en) * 1974-10-04 1977-01-04 Barrett M James Covalently bound biological substances to plastic materials and use in radioassay
SE400173B (en) * 1975-03-20 1978-03-20 Aminkemi Ab PROCEDURE FOR STABILIZING A HEPARINIZED SURFACE CONTAINING FOR BLOOD CONTACT RELEASE HEPARIN
US4102746A (en) * 1975-08-29 1978-07-25 Amerace Corporation Immobilized proteins
US4273833A (en) * 1975-09-19 1981-06-16 United States Trading International, Inc. Anti-fouling overcoating composition and use thereof
FR2324664A1 (en) * 1975-09-22 1977-04-15 Rhone Poulenc Ind POLYURETHANES FOR ITEMS FOR MEDICAL USE
CA1083508A (en) * 1975-11-13 1980-08-12 Jacques Grange Supports having lateral chains, process for obtaining such supports, process for the fixation of organic compounds comprising a glucidic residue on said supports, products and reactives from said chimical fixation
US4048064A (en) * 1976-04-23 1977-09-13 Clark Iii William T Biocompatible hemoperfusion system
US4141857A (en) * 1976-04-30 1979-02-27 Uop Inc. Support matrices for immobilized enzymes
US4192727A (en) * 1976-08-24 1980-03-11 Union Carbide Corporation Polyelectrolyte hydrogels and methods of their preparation
US4349467A (en) * 1977-01-31 1982-09-14 Williams Joel L Nonthrombogenic articles and method of preparation
US4116898A (en) * 1977-01-31 1978-09-26 Becton, Dickinson And Company Non-thrombogenic articles
JPS5413694A (en) * 1977-07-01 1979-02-01 Sumitomo Electric Industries Composite blood vessel prosthesis and method of producing same
SE425372B (en) * 1977-07-18 1982-09-27 Ird Biomaterial Ab SET TO HEPARINIZE AN ELECTRICALLY CHARGED SURFACE ON A MEDICAL ARTICLE INTENDED TO CONTACT WITH BLOOD AND MEDICINES TO PERFORM THE SET
US4166152B1 (en) * 1977-08-17 1999-05-18 Minnesota Mining & Mfg Tacky polymeric microspheres
US4273873A (en) * 1977-10-25 1981-06-16 Unitika Ltd. Preparation of antithrombogenic polymeric materials
US4278651A (en) * 1978-09-27 1981-07-14 Becton Dickinson & Company Supported receptor and use thereof in an assay
US4239664A (en) * 1978-10-31 1980-12-16 Research Corporation Anti-thrombogenic PVP-heparin polymer
GB2041377B (en) 1979-01-22 1983-09-28 Woodroof Lab Inc Bio compatible and blood compatible materials and methods
US4301067A (en) * 1979-06-05 1981-11-17 Kureha Kagaku Kogyo Kabushiki Kaisha Chitin containing poly-ion complex
US4272518A (en) * 1979-07-10 1981-06-09 Moro Daniel G Plastic wound bandage
US4329383A (en) * 1979-07-24 1982-05-11 Nippon Zeon Co., Ltd. Non-thrombogenic material comprising substrate which has been reacted with heparin
US4268423A (en) * 1979-11-16 1981-05-19 Uop Inc. Support matrices for immobilized enzymes
IT1141483B (en) * 1980-04-18 1986-10-01 Crinos Industria Farmaco POLYAMIN RESIN FOR THE SELECTIVE SEPARATION OF HEPARIN FROM OTHER GLUCOSAMINOGLICANS AND PROCEDURE FOR ITS PREPARATION
US4423099A (en) * 1980-07-28 1983-12-27 Ciba-Geigy Corporation Membrane modified hydrogels
US4331697A (en) * 1980-09-02 1982-05-25 Teijin Limited Novel heparin derivative, method for production thereof, and method for rendering biomedical materials antithrombotic by use of the novel heparin derivative
CA1160548A (en) 1980-09-24 1984-01-17 Rolf L. Larsson Method for detecting proteolytic enzymes in blood
US4326532A (en) * 1980-10-06 1982-04-27 Minnesota Mining And Manufacturing Company Antithrombogenic articles
US4424346A (en) * 1981-06-04 1984-01-03 Canadian Patents And Development Ltd. Derivatives of chitins, chitosans and other polysaccharides
US4350806A (en) * 1981-09-28 1982-09-21 Akzona Incorporated Biocompatible copolymers
US4526714A (en) * 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
SE456347B (en) * 1982-02-09 1988-09-26 Ird Biomaterial Ab SURFACE MODIFIED SOLID SUBSTRATE AND PROCEDURES FOR PRODUCING THEREOF
SE8200751L (en) * 1982-02-09 1983-08-10 Olle Larm PROCEDURE FOR COVALENT COUPLING FOR MANUFACTURE OF CONJUGATE AND REQUIRED PRODUCTS
US4737544A (en) * 1982-08-12 1988-04-12 Biospecific Technologies, Inc. Biospecific polymers
US5258041A (en) * 1982-09-29 1993-11-02 Bio-Metric Systems, Inc. Method of biomolecule attachment to hydrophobic surfaces
US5217492A (en) * 1982-09-29 1993-06-08 Bio-Metric Systems, Inc. Biomolecule attachment to hydrophobic surfaces
US4613517A (en) * 1983-04-27 1986-09-23 Becton, Dickinson And Company Heparinization of plasma treated surfaces
US4521564A (en) * 1984-02-10 1985-06-04 Warner-Lambert Company Covalent bonded antithrombogenic polyurethane material
AU566085B2 (en) * 1984-06-04 1987-10-08 Terumo Kabushiki Kaisha Medical instrument with surface treatment
DE3422494A1 (en) * 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen METHOD AND DEVICE FOR SPECIFIC ADSORPTION OF HEPARIN
US4996150A (en) * 1984-10-29 1991-02-26 Amoco Corporation Biocatalyst immobilization in a gel of anionic polysaccharide and cationic polymer
US4642242A (en) * 1985-04-01 1987-02-10 Becton, Dickinson And Company Permanently bonded antithrombogenic polyurethane surface
US4600652A (en) * 1985-04-01 1986-07-15 Warner-Lambert Company Permanently bonded antithrombogenic polyurethane surface
DE3519011A1 (en) * 1985-05-25 1986-11-27 Behringwerke Ag, 3550 Marburg METHOD FOR PRODUCING A MATERIAL FOR AFFINITY CHROMATOGRAPHY
CH665954A5 (en) * 1985-07-08 1988-06-30 Battelle Memorial Institute SUBSTRATE WITH A SURFACE OF ANTITHROMBOGENIC ACTIVITY.
JPS6238172A (en) * 1985-08-12 1987-02-19 株式会社　高研 Production of anti-thrombotic medical material
JPS62124976A (en) * 1985-11-26 1987-06-06 Canon Inc Recording material
US4708981A (en) * 1985-12-11 1987-11-24 Uop Inc. Water insoluble proton conducting polymers
IT1213023B (en) * 1986-01-16 1989-12-07 Rolando Barbucci MATERIAL ABLE TO ADSORBE STABLY HIGH QUANTITIES OF HEPARIN, AND ITS PREPARATION PROCEDURE.
US4871357A (en) * 1986-01-21 1989-10-03 Baxter International Inc. Ionic heparin coating
US4720512A (en) * 1986-03-24 1988-01-19 Becton, Dickinson And Company Polymeric articles having enhanced antithrombogenic activity
US4786556A (en) * 1986-03-24 1988-11-22 Becton, Dickinson And Company Polymeric articles having enhanced antithrombogenic activity
US5069945A (en) * 1986-10-20 1991-12-03 Memtec America Corporation Ultrapous thin-film membranes
US4800016A (en) * 1986-11-24 1989-01-24 The University Of Michigan Extracorporeal blood de-heparinization system
US4863611A (en) * 1987-04-30 1989-09-05 Massachusetts Institute Of Technology Extracorporeal reactors containing immobilized species
NL8701337A (en) * 1987-06-09 1989-01-02 Sentron V O F SUBSTRATE PROVIDED WITH A BLOOD COMPATIBLE SURFACE OBTAINED BY COUPLING WITH THE SURFACE OF A PHYSIOLOGICALLY ACTIVE SUBSTANCE WITH AN INHIBITORY INFLUENCE ON THE FORMATION OF BLOOD CLOTS AND / OR CONTAINED FROM HARMFOLIC CIRCULARS.
US5047020A (en) * 1987-09-14 1991-09-10 Baxter International Inc. Ionic heparin coating
JP2561309B2 (en) * 1988-03-28 1996-12-04 テルモ株式会社 Medical material and manufacturing method thereof
US5013717A (en) * 1988-04-18 1991-05-07 Becton, Dickinson And Company Blood compatible, lubricious article and composition and method therefor
US5182317A (en) * 1988-06-08 1993-01-26 Cardiopulmonics, Inc. Multifunctional thrombo-resistant coatings and methods of manufacture
US4865870A (en) * 1988-07-07 1989-09-12 Becton, Dickinson And Company Method for rendering a substrate surface antithrombogenic
US5053048A (en) * 1988-09-22 1991-10-01 Cordis Corporation Thromboresistant coating
US5000854A (en) * 1989-06-14 1991-03-19 The University Of Michigan Protamine-based filter device for removal of heparin from blood samples
US5476715A (en) 1989-10-03 1995-12-19 Fresenius Ag Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits
US5049403A (en) * 1989-10-12 1991-09-17 Horsk Hydro A.S. Process for the preparation of surface modified solid substrates
US5213898A (en) * 1989-10-12 1993-05-25 Norsk Hydro A.S. Process for the preparation of surface modified solid substrates
US5219926A (en) * 1989-12-29 1993-06-15 Berol Nobel Ab Method of covalently bonding biopolymer to a solid hydrophilic organic polymer
US5087671A (en) * 1990-06-25 1992-02-11 The Curators Of The University Of Missouri Polymers for scavenging nitrosating agents
US5151192A (en) * 1990-07-13 1992-09-29 Pall Corporation Method for removing heparin from blood or plasma
SE466754B (en) * 1990-09-13 1992-03-30 Berol Nobel Ab COVALENT BINDING POLYMERS TO HYDROPHILIC SURFACES
SE467308B (en) * 1990-10-22 1992-06-29 Berol Nobel Ab SOLID SURFACE COATED WITH A HYDROPHILIC SURFACE WITH COVALENTLY BONDED BIOPOLYMERS, SET TO MAKE SUCH A SURFACE AND CONJUGATED THEREOF
SE467309B (en) * 1990-10-22 1992-06-29 Berol Nobel Ab HYDROPHILIZED FIXED SURFACE, PROCEDURE FOR ITS PREPARATION AND AGENTS THEREOF
US5132108A (en) * 1990-11-08 1992-07-21 Cordis Corporation Radiofrequency plasma treated polymeric surfaces having immobilized anti-thrombogenic agents
US5159050A (en) * 1991-05-09 1992-10-27 Becton, Dickinson And Company Polyurethane and medical article therefrom
US5211850A (en) * 1991-07-26 1993-05-18 Research Medical, Inc. Plasma filter sorbent system for removal of components from blood
AU3124793A (en) 1991-10-29 1993-06-07 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
US5145956A (en) * 1991-12-11 1992-09-08 Glycomed Incorporated Method for separation of anionic oligosaccharides
EP0585436B1 (en) 1992-02-13 2000-05-03 SurModics, Inc. Immobilization of chemical species in crosslinked matrices
JPH05220218A (en) 1992-02-13 1993-08-31 Norio Nakabayashi Anti-thrombogenic regeneration cellulose film and manufacture thereof
US5391580A (en) 1992-03-20 1995-02-21 Anatrace Inc. Poly(sulfone-alpha-olefin) composite permselective membrane article for use in blood oxygenation
US5212008A (en) * 1992-04-01 1993-05-18 Xerox Corporation Coated recording sheets
US5906734A (en) 1992-06-19 1999-05-25 Biosepra Inc. Passivated porous polymer supports and methods for the preparation and use of same
US5350800A (en) * 1993-01-19 1994-09-27 Medtronic, Inc. Method for improving the biocompatibility of solid surfaces
US5308641A (en) * 1993-01-19 1994-05-03 Medtronic, Inc. Biocompatibility of solid surfaces
US5416198A (en) 1993-02-05 1995-05-16 Research Medical, Inc. Selective sorbent removal system using polycation activated substrates
GB9306222D0 (en) 1993-03-25 1993-05-19 Zeneca Ltd Dispersants
US5614310A (en) 1994-11-04 1997-03-25 Minnesota Mining And Manufacturing Company Low trauma wound dressing with improved moisture vapor permeability
US5700559A (en) 1994-12-16 1997-12-23 Advanced Surface Technology Durable hydrophilic surface coatings
US5576072A (en) 1995-02-01 1996-11-19 Schneider (Usa), Inc. Process for producing slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with at least one other, dissimilar polymer hydrogel
US5532311A (en) 1995-02-01 1996-07-02 Minnesota Mining And Manufacturing Company Process for modifying surfaces
US5702754A (en) 1995-02-22 1997-12-30 Meadox Medicals, Inc. Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings
US5688855A (en) 1995-05-01 1997-11-18 S.K.Y. Polymers, Inc. Thin film hydrophilic coatings
US5766478A (en) 1995-05-30 1998-06-16 The Regents Of The University Of California, Office Of Technology Transfer Water-soluble polymers for recovery of metal ions from aqueous streams
US5672638A (en) 1995-08-22 1997-09-30 Medtronic, Inc. Biocompatability for solid surfaces
US5607475A (en) 1995-08-22 1997-03-04 Medtronic, Inc. Biocompatible medical article and method
US5662985A (en) 1996-05-21 1997-09-02 Mobil Oil Corporation Two-side coated label facestock
US5811151A (en) 1996-05-31 1998-09-22 Medtronic, Inc. Method of modifying the surface of a medical device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0351314A2 (en) * 1988-07-11 1990-01-17 Terumo Kabushiki Kaisha Medical material and medical implement
EP0693293A1 (en) * 1994-07-07 1996-01-24 Terumo Kabushiki Kaisha Medical instruments that exhibit surface lubricity when wetted
WO1997046590A1 (en) * 1996-06-03 1997-12-11 Gore Enterprise Holdings, Inc. Materials and methods for the immobilization of bioactive species onto polymeric substrates

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027444A1 (en) * 1998-11-09 2000-05-18 Ecole Polytechnique Federale De Lausanne Functionalised polymers for tissue engineering
WO2000041739A1 (en) * 1999-01-15 2000-07-20 University Of Utah Research Foundation Attachment of acid moiety-containing biomolecules to activated polymeric surfaces
EP1088564A1 (en) * 1999-09-30 2001-04-04 Orbus Medical Technologies, Inc. Intraluminal device, coating for such device, as well as a method for preparing the intraluminal device
WO2001023016A1 (en) * 1999-09-30 2001-04-05 Orbus Medical Technologies Inc. Intraluminal device, coating for such device, and method for preparing said device
US7955612B1 (en) 1999-09-30 2011-06-07 Orbusneich Medical, Inc. Intraluminal device, coating for such device, and method for preparing said device

Also Published As

Publication number Publication date
JP4339413B2 (en) 2009-10-07
EP1021216A1 (en) 2000-07-26
US6146771A (en) 2000-11-14
JP2002514126A (en) 2002-05-14
AU5166298A (en) 1999-01-25

Similar Documents

Publication Publication Date Title
US6146771A (en) Process for modifying surfaces using the reaction product of a water-insoluble polymer and a polyalkylene imine
EP2340057B1 (en) Immobilised biological entities
EP1553993B1 (en) Surface coating comprising bioactive compound
US5429618A (en) Thromboresistant articles
JP6683551B2 (en) Fixed biological entity
WO1993005825A1 (en) Processes for reducing the thrombogenicity of biomaterials
WO2005118020A1 (en) Surface coating comprising bioactive compound
WO1999001195A1 (en) Removal of biologically active agents
US7468210B1 (en) Cross-linked heparin coatings and methods
CA2392080C (en) Blood-compatible polymer surfaces
Balakrishnan et al. Chemical modification of poly (vinyl chloride) using poly (ethylene glycol) to improve blood compatibility
JPH02144070A (en) Easily slidable medical material
CN115721786B (en) Functional medical coating and preparation method thereof
KR19990038671A (en) Hemocompatible Polyurethane-Hydrophilic Polymer Blend
JPH09131396A (en) Anti-thrombogenic medical base and its manufacture
JP2000516827A (en) Biocompatible medical products and methods
JPH03188868A (en) Manufacture of medical material
JPH0678382B2 (en) Method for producing hydrophilic polymer material having excellent anticoagulability

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1997946507

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997946507

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997946507

Country of ref document: EP